Study reveals the function of a specific protein works differently in the brains of men and women. The findings help explain why some psychiatric disorders and resistance to treatments vary between the sexes.
Using over a century of data from other pandemics, and applying knowledge about the current COVID-19 infection, researchers predict the long term effects coronavirus will have on the brain and nervous system.
Treatment with LAU-0901, a synthetic molecule that blocks pro-inflammatory platelet-activating factor, in addition to aspirin-triggered NPD1, reduced the size of damage areas in the brain, initiated repair mechanisms, and improved behavioral recovery following ischemic stroke.
Researchers have isolated a set of antibodies from a llama which show promise for the treatment of COVID-19. The NIH-CoVnB-112 nanoantibody bound to ACE2 receptors up to ten times stronger than other lab-produced antibodies. The nanoantibody stuck directly to the ACE2 receptor binding portion of the SARS_CoV-2 spike protein. The protein could be effective in preventing coronavirus infection.
A new small scale study reveals the antidepressant fluvoxamine may be a new tool in the fight against COVID-19. Researchers report fluvoxamine reduced the severity of coronavirus symptoms and hospitalizations.
Altered microRNA levels in a person's saliva can help determine if they have experienced a recent concussion. The new saliva test is a cheap and non-invasive method for the identification of concussion.
Placebos reduce biomarkers in the brain of emotional distress, even when a patient knows they are taking one.
Famotidine (Pepcid AC), an over-the-counter medication used to treat indigestion, shows promise as a potential treatment for COVID-19.
Treating coronavirus patients with alpha-blockers may help prevent the cytokine storm associated with severe COVID-19 infection. Alpha-blockers interfere with the cell signaling that triggers cytokine storms. Mice with bacterial infections that were treated with alpha-blockers experienced reduced cytokine storms and decreased death rates.
Coronavirus patients treated with chloroquine or hydroxychloroquine are significantly more likely to experience ventricular arrhythmias than those who were treated with other medications. The study also revealed that out of 100,000 COVID-19 patients who were hospitalized, the 15,000 who received hydroxychloroquine were more likely to have worse health outcomes than those treated with other drugs.